{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:19:43Z","timestamp":1648973983189},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00393-013-1137-6","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T05:32:20Z","timestamp":1383629540000},"page":"853-866","source":"Crossref","is-referenced-by-count":0,"title":["Etablierte Medikamente"],"prefix":"10.1007","volume":"72","author":[{"given":"I.","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,7]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11926-011-0172-z","volume":"13","author":"Aggarwal","year":"2011","unstructured":"Aggarwal R, Oddis CV (2011) Therapeutic approaches in myositis. Curr Rheumatol Rep 13:182\u2013191","journal-title":"Curr Rheumatol Rep"},{"key":"1137_CR2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Anonymous","year":"2005","unstructured":"Anonymous (2005) Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 352:351\u2013361","journal-title":"N Engl J Med"},{"key":"1137_CR3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"5","author":"Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 5:1103\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1137_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E et al (2011) Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"1137_CR5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0961203311426569","volume":"21","author":"Aringer","year":"2012","unstructured":"Aringer M, Burkhardt H, Burmester GR et al (2012) Current state of evidence on \u201aoff-label\u2018 therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland \u2013 a consensus report. Lupus 21:386\u2013401","journal-title":"Lupus"},{"key":"1137_CR6","unstructured":"Aringer M, Fischer-Betz R, Hiepe F, Kommission Pharmakotherapie der DGRh (2013) Stellungnahme zum Einsatz von Mycophenolat-Mofetil bei SLE. Homepage der DGRh. http:\/\/dgrh.de\/mmf.html. Zugegriffen am 22.09.2013"},{"key":"1137_CR7","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","volume":"50","author":"Aringer","year":"2004","unstructured":"Aringer M, Graninger WB, Steiner G et al (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50:3161\u20133169","journal-title":"Arthritis Rheum"},{"key":"1137_CR8","doi-asserted-by":"crossref","unstructured":"Aringer M, Houssiau F, Gordon C et al (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48:1451\u20131454","DOI":"10.1093\/rheumatology\/kep270"},{"key":"1137_CR9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","volume":"11","author":"Aringer","year":"2012","unstructured":"Aringer M, Smolen JS (2012) Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 11:321\u2013325","journal-title":"Autoimmun Rev"},{"key":"1137_CR10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","volume":"20","author":"Austin","year":"2009","unstructured":"Austin HA 3rd, Illei GG, Braun MJ et al. (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20:901\u2013911","journal-title":"J Am Soc Nephrol"},{"key":"1137_CR11","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","volume":"69","author":"Bertsias","year":"2010","unstructured":"Bertsias GK, Ioannidis JP, Aringer M et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074\u20132082","journal-title":"Ann Rheum Dis"},{"key":"1137_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JP, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195\u2013205","journal-title":"Ann Rheum Dis"},{"key":"1137_CR13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League against rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71:1771\u20131782","journal-title":"Ann Rheum Dis"},{"key":"1137_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/BOR.0b013e32834d5730","volume":"24","author":"Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, Fervenza FC, Specks U (2012) Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol 24:15\u201323","journal-title":"Curr Opin Rheumatol"},{"key":"1137_CR15","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1093\/ndt\/gfq322","volume":"25","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2010","unstructured":"Cort\u00e9s-Hern\u00e1ndez J, Torres-Salido MT, Medrano AS et al (2010) Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 25:3939\u20133948","journal-title":"Nephrol Dial Transplant"},{"key":"1137_CR16","doi-asserted-by":"crossref","unstructured":"Couderc M, Gottenberg JE, Mariette X et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50:2283\u20132289","DOI":"10.1093\/rheumatology\/ker305"},{"key":"1137_CR17","doi-asserted-by":"crossref","first-page":"214013","DOI":"10.1155\/2011\/214013","volume":"2011","author":"Daoussis","year":"2011","unstructured":"Daoussis D, Liossis SN, Yiannopoulos G et al (2011) B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011:214013","journal-title":"Int J Rheumatol"},{"key":"1137_CR18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"Dass","year":"2008","unstructured":"Dass S, Bowman SJ, Vital EM et al (2008) Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67:1541\u20131544","journal-title":"Ann Rheum Dis"},{"key":"1137_CR19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670\u20131677","journal-title":"Ann Rheum Dis"},{"key":"1137_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/art.37758","volume":"65","author":"De","year":"2013","unstructured":"De Visser M (2013) The efficacy of rituximab in refractory myositis: the jury is still out. Arthritis Rheum 65:303\u2013306","journal-title":"Arthritis Rheum"},{"key":"1137_CR21","doi-asserted-by":"crossref","unstructured":"Derk CT, Grace E, Shenin M et al (2009) A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 48:1595\u20131599","DOI":"10.1093\/rheumatology\/kep295"},{"key":"1137_CR22","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, Mohle A et al (2010) Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet\u2019s disease. Arthritis Rheum 62:2796\u20132805","journal-title":"Arthritis Rheum"},{"key":"1137_CR23","first-page":"S40","volume":"29","author":"Distler","year":"2011","unstructured":"Distler JH, Jordan S, Airo P et al (2011) Is there a role for TNFalpha antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 29:S40\u2013S45","journal-title":"Clin Exp Rheumatol"},{"key":"1137_CR24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217\u20131220","journal-title":"Ann Rheum Dis"},{"key":"1137_CR25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0961203309351541","volume":"19","author":"Garcia-Carrasco","year":"2010","unstructured":"Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M et al (2010) Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 19:213\u2013219","journal-title":"Lupus"},{"key":"1137_CR26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1191\/096120399678840927","volume":"8","author":"Gaubitz","year":"1999","unstructured":"Gaubitz M, Schorat A, Schotte H et al (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731\u2013736","journal-title":"Lupus"},{"key":"1137_CR27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.25052","volume":"62","author":"Ginzler","year":"2010","unstructured":"Ginzler EM, Appel GB, Dooley MA et al (2010) Aspreva Lupus Management Study (ALMS): Maintenance Results. Arthritis Rheum 62(Suppl 10):2085","journal-title":"Arthritis Rheum"},{"key":"1137_CR28","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219\u20132228","journal-title":"N Engl J Med"},{"key":"1137_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","volume":"62","author":"Ginzler","year":"2010","unstructured":"Ginzler EM, Wofsy D, Isenberg D et al (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62:211\u2013221","journal-title":"Arthritis Rheum"},{"key":"1137_CR30","doi-asserted-by":"crossref","unstructured":"Griffiths B, Emery P, Ryan V et al (2010) The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 49:723\u2013732","DOI":"10.1093\/rheumatology\/kep396"},{"key":"1137_CR31","doi-asserted-by":"crossref","unstructured":"Guerry MJ, Brogan P, Bruce IN et al (2012) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51:634\u2013643","DOI":"10.1093\/rheumatology\/ker150"},{"key":"1137_CR32","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"Gunnarsson","year":"2007","unstructured":"Gunnarsson I, Sundelin B, J\u00f3nsd\u00f3ttir T et al (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 56:1263\u20131272","journal-title":"Arthritis Rheum"},{"key":"1137_CR33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","volume":"Res","author":"Hahn","year":"2012","unstructured":"Hahn BH, Mcmahon MA, Wilkinson A et al (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64:797\u2013808","journal-title":"Arthritis Care"},{"key":"1137_CR34","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"1137_CR35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.ajkd.2012.08.041","volume":"61","author":"Henderson","year":"2013","unstructured":"Henderson LK, Masson P, Craig JC et al (2013) Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 61:74\u201387","journal-title":"Am J Kidney Dis"},{"key":"1137_CR36","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s10067-007-0643-9","volume":"26","author":"Henes","year":"2007","unstructured":"Henes JC, Fritz J, Koch S et al (2007) Rituximab for treatment-resistant extensive Wegener\u2019s granulomatosis \u2013 additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 26:1711\u20131715","journal-title":"Clin Rheumatol"},{"key":"1137_CR37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-010-1462-x","volume":"31","author":"Henes","year":"2011","unstructured":"Henes JC, Kanz L, Koetter I (2011) Rituximab and leflunomide for Wegener\u2019s granulomatosis: a long-term follow-up. Rheumatol Int 31:425\u2013426","journal-title":"Rheumatol Int"},{"key":"1137_CR38","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381\u20132388","journal-title":"JAMA"},{"key":"1137_CR39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621\u2013630","journal-title":"Ann Intern Med"},{"key":"1137_CR40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","volume":"71","author":"Holle","year":"2012","unstructured":"Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327\u2013333","journal-title":"Ann Rheum Dis"},{"key":"1137_CR41","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"Houssiau","year":"2010","unstructured":"Houssiau FA, D\u2019Cruz D, Sangle S et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69:2083\u20132089","journal-title":"Ann Rheum Dis"},{"key":"1137_CR42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"Illei","year":"2010","unstructured":"Illei GG, Shirota Y, Yarboro CH et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542\u2013552","journal-title":"Arthritis Rheum"},{"key":"1137_CR43","doi-asserted-by":"crossref","unstructured":"Jayne D (2007) Leflunomide versus methotrexate in Wegener\u2019s granulomatosis. Rheumatology (Oxford) 46:1047\u20131048","DOI":"10.1093\/rheumatology\/kem050"},{"key":"1137_CR44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36\u201344","journal-title":"N Engl J Med"},{"key":"1137_CR45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220","journal-title":"N Engl J Med"},{"key":"1137_CR46","doi-asserted-by":"crossref","unstructured":"J\u00f3nsd\u00f3ttir T, Gunnarsson I, Mour\u00e3o AF et al (2010) Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 49:1502\u20131504","DOI":"10.1093\/rheumatology\/keq055"},{"key":"1137_CR47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"Kotter","year":"2004","unstructured":"Kotter I, Gunaydin I, Zierhut M et al (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320\u2013335","journal-title":"Semin Arthritis Rheum"},{"key":"1137_CR48","first-page":"S114","volume":"30","author":"Kotter","year":"2012","unstructured":"Kotter I, Henes JC, Wagner AD et al (2012) Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 30:S114\u2013S129","journal-title":"Clin Exp Rheumatol"},{"key":"1137_CR49","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"1137_CR50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3899\/jrheum.120682","volume":"40","author":"Lazarou","year":"2013","unstructured":"Lazarou IN, Guerne PA (2013) Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 40:550\u2013564","journal-title":"J Rheumatol"},{"key":"1137_CR51","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/0961203310366573","volume":"19","author":"Lee","year":"2010","unstructured":"Lee T, Oh KH, Joo KW et al (2010) Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus 19:974\u2013980","journal-title":"Lupus"},{"key":"1137_CR52","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","volume":"70","author":"Le","year":"2011","unstructured":"Le EN, Wigley FM, Shah AA et al (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104\u20131107","journal-title":"Ann Rheum Dis"},{"key":"1137_CR53","first-page":"S70","volume":"30","author":"Loock","year":"2012","unstructured":"Loock J, Henes J, Kotter I et al (2012) Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 30:S70\u2013S76","journal-title":"Clin Exp Rheumatol"},{"key":"1137_CR54","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580\u20132589","journal-title":"Arthritis Rheum"},{"key":"1137_CR55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","volume":"61","author":"Lu","year":"2009","unstructured":"Lu TY, Ng KP, Cambridge G et al (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61:482\u2013487","journal-title":"Arthritis Rheum"},{"key":"1137_CR56","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S et al (2004) Inefficacy of infliximab in primary Sjogren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS). Arthritis Rheum 50:1270\u20131276","journal-title":"Arthritis Rheum"},{"key":"1137_CR57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","volume":"67","author":"Martinez-Taboada","year":"2008","unstructured":"Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625\u2013630","journal-title":"Ann Rheum Dis"},{"key":"1137_CR58","first-page":"416","volume":"27","author":"Matsumura","year":"2009","unstructured":"Matsumura R, Umemiya K, Sugiyama T et al (2009) Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 27:416\u2013421","journal-title":"Clin Exp Rheumatol"},{"key":"1137_CR59","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960\u2013968","journal-title":"Arthritis Rheum"},{"key":"1137_CR60","first-page":"98","volume":"32","author":"Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J Rheumatol 32:98\u2013105","journal-title":"J Rheumatol"},{"key":"1137_CR61","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"Mendoza","year":"2012","unstructured":"Mendoza FA, Nagle SJ, Lee JB et al (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39:1241\u20131247","journal-title":"J Rheumatol"},{"key":"1137_CR62","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"Merrill","year":"2010","unstructured":"Merrill JT, Burgos-Vargas R, Westhovens R et al (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:3077\u20133087","journal-title":"Arthritis Rheum"},{"key":"1137_CR63","doi-asserted-by":"crossref","unstructured":"Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis. Rheumatology (Oxford) 46:1087\u20131091","DOI":"10.1093\/rheumatology\/kem029"},{"key":"1137_CR64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1191\/0961203304lu1047cr","volume":"13","author":"Moosig","year":"2004","unstructured":"Moosig F, Zeuner R, Renk C, Schr\u00f6der JO (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13:605\u2013606","journal-title":"Lupus"},{"key":"1137_CR65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","volume":"1","author":"Moroni","year":"2006","unstructured":"Moroni G, Doria A, Mosca M et al. (2006) A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1:925\u2013932","journal-title":"Clin J Am Soc Nephrol"},{"key":"1137_CR66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318\u2013323","journal-title":"Ann Rheum Dis"},{"key":"1137_CR67","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68:310\u2013317","journal-title":"Ann Rheum Dis"},{"key":"1137_CR68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314\u2013324","journal-title":"Arthritis Rheum"},{"key":"1137_CR69","first-page":"S55","volume":"30","author":"Omair","year":"2012","unstructured":"Omair MA, Phumethum V, Johnson SR (2012) Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 30:S55\u2013S59","journal-title":"Clin Exp Rheumatol"},{"key":"1137_CR70","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2004.025858","volume":"64","author":"Ostendorf","year":"2005","unstructured":"Ostendorf B, Iking-Konert C, Kurz K et al (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64:630\u2013633","journal-title":"Ann Rheum Dis"},{"key":"1137_CR71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.100361","volume":"38","author":"Phumethum","year":"2011","unstructured":"Phumethum V, Jamal S, Johnson SR (2011) Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 38:289\u2013296","journal-title":"J Rheumatol"},{"key":"1137_CR72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/acr.20689","volume":"Res","author":"Puechal","year":"2012","unstructured":"Puechal X, Gottenberg JE, Berthelot JM et al (2012) Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 64:331\u2013339","journal-title":"Arthritis Care"},{"key":"1137_CR73","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zeron P, Munoz S et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 86:242\u2013251","journal-title":"Medicine"},{"key":"1137_CR74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","volume":"304","author":"Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Tzioufas AG, Stone JH et al (2010) Treatment of primary Sjogren syndrome: a systematic review. JAMA 304:452\u2013460","journal-title":"JAMA"},{"key":"1137_CR75","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215\u20131226","journal-title":"Arthritis Rheum"},{"key":"1137_CR76","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"Sankar","year":"2004","unstructured":"Sankar V, Brennan MT, Kok MR et al (2004) Etanercept in Sjogren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50:2240\u20132245","journal-title":"Arthritis Rheum"},{"key":"1137_CR77","doi-asserted-by":"crossref","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet\u2019s disease \u2013 review and basis for recommendations. Rheumatology (Oxford) 46:736\u2013741","DOI":"10.1093\/rheumatology\/kem034"},{"key":"1137_CR78","doi-asserted-by":"crossref","unstructured":"Shima Y, Kuwahara Y, Murota H et al (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49:2408\u20132412","DOI":"10.1093\/rheumatology\/keq275"},{"key":"1137_CR79","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.30394","volume":"63","author":"Silva","year":"2011","unstructured":"Silva F, Seo P, Schroeder DR et al (2011) Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener\u2019s): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 63:2495\u20132503","journal-title":"Arthritis Rheum"},{"key":"1137_CR80","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry MJ et al (2012) Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3760\u20133769","journal-title":"Arthritis Rheum"},{"key":"1137_CR81","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","volume":"64","author":"Sneller","year":"2012","unstructured":"Sneller MC, Hu Z, Langford CA (2012) A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64:835\u2013842","journal-title":"Arthritis Rheum"},{"key":"1137_CR82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"1137_CR83","doi-asserted-by":"crossref","unstructured":"Szeto CC, Kwan BC, Lai FM et al (2008) Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47:1678\u20131681","DOI":"10.1093\/rheumatology\/ken335"},{"key":"1137_CR84","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458\u20132466","journal-title":"Arthritis Rheum"},{"key":"1137_CR85","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","volume":"Res","author":"Terrier","year":"2010","unstructured":"Terrier B, Launay D, Kaplanski G et al (2010) Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) 62:1787\u20131795","journal-title":"Arthritis Care"},{"key":"1137_CR86","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"Tokunaga","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D et al (2007) Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66:470\u2013475","journal-title":"Ann Rheum Dis"},{"key":"1137_CR87","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13:R75","journal-title":"Arthritis Res Ther"},{"key":"1137_CR88","doi-asserted-by":"crossref","first-page":"143637","DOI":"10.1155\/2012\/143637","volume":"2012","author":"Tzouvelekis","year":"2012","unstructured":"Tzouvelekis A, Galanopoulos N, Bouros E et al (2012) Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012:143637","journal-title":"Pulm Med"},{"key":"1137_CR89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32835b133a","volume":"25","author":"Unizony","year":"2013","unstructured":"Unizony S, Stone JH, Stone JR (2013) New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 25:3\u20139","journal-title":"Curr Opin Rheumatol"},{"key":"1137_CR90","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","volume":"66","author":"Van","year":"2007","unstructured":"Van Woerkom JM, Kruize AA, Geenen R et al (2007) Safety and efficacy of leflunomide in primary Sjogren\u2019s syndrome: a phase II pilot study. Ann Rheum Dis 66:1026\u20131032","journal-title":"Ann Rheum Dis"},{"key":"1137_CR91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","volume":"28","author":"Weidenbusch","year":"2013","unstructured":"Weidenbusch M, Rommele C, Schrottle A et al (2013) Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 28:106\u2013111","journal-title":"Nephrol Dial Transplant"},{"key":"1137_CR92","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","volume":"64","author":"Wofsy","year":"2012","unstructured":"Wofsy D, Hillson JL, Diamond B (2012) Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64:3660\u20133665","journal-title":"Arthritis Rheum"},{"key":"1137_CR93","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.37940","volume":"65","author":"Wofsy","year":"2013","unstructured":"Wofsy D, Hillson JL, Diamond B (2013) Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 65:1586\u20131591","journal-title":"Arthritis Rheum"},{"key":"1137_CR94","doi-asserted-by":"crossref","unstructured":"Xenitidis T, Horger M, Zeh G et al (2013) Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 52:1729\u20131731","DOI":"10.1093\/rheumatology\/ket107"},{"key":"1137_CR95","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, Tuzun Y et al (2001) A double-blind trial of colchicine in Behcet\u2019s syndrome. Arthritis Rheum 44:2686\u20132692","journal-title":"Arthritis Rheum"},{"key":"1137_CR96","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","volume":"19","author":"Zavada","year":"2010","unstructured":"Zavada J, Pesickova S, Rysava R et al (2010) Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19:1281\u20131289","journal-title":"Lupus"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1137-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1137-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1137-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T21:09:10Z","timestamp":1564607350000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1137-6"}},"subtitle":["Neue Einsatzgebiete"],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1137-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}